Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACIP consideration of vaccine cost is appropriate in coverage decisions, CDC official testifies.

Executive Summary

ACIP CONSIDERATION OF VACCINE COST-BENEFIT IS APPROPRIATE, CDC's ORENSTEIN testified at a July 16 Senate Appropriations/Labor & HHS Subcommittee hearing on vaccines. "It is extremely important that [the Advisory Committee on Immunization Practices] take cost-benefit and cost effectiveness into account in their recommendations because...their recommendations go beyond what the government purchases. These are recommendations that basically address public health practices," Centers for Disease Control & Prevention National Immunization Program Director Walter Orenstein, MD, testified.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel